Infant Bacterial Therapeutics AB (publ)

OM:IBT B Stock Report

Market Cap: SEK 514.6m

Infant Bacterial Therapeutics Management

Management criteria checks 2/4

Infant Bacterial Therapeutics' CEO is Staffan Stromberg, appointed in Jan 2013, has a tenure of 11.83 years. total yearly compensation is SEK5.33M, comprised of 57.9% salary and 42.1% bonuses, including company stock and options. directly owns 0.79% of the company’s shares, worth SEK4.08M. The average tenure of the management team and the board of directors is 1.5 years and 7.5 years respectively.

Key information

Staffan Stromberg

Chief executive officer

SEK 5.3m

Total compensation

CEO salary percentage57.9%
CEO tenure11.8yrs
CEO ownership0.8%
Management average tenure1.5yrs
Board average tenure7.5yrs

Recent management updates

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07
Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

CEO Compensation Analysis

How has Staffan Stromberg's remuneration changed compared to Infant Bacterial Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 144m

Jun 30 2024n/an/a

-SEK 142m

Mar 31 2024n/an/a

-SEK 128m

Dec 31 2023SEK 5mSEK 3m

-SEK 123m

Sep 30 2023n/an/a

-SEK 122m

Jun 30 2023n/an/a

-SEK 99m

Mar 31 2023n/an/a

-SEK 69m

Dec 31 2022SEK 6mSEK 3m

-SEK 65m

Sep 30 2022n/an/a

-SEK 42m

Jun 30 2022n/an/a

-SEK 34m

Mar 31 2022n/an/a

-SEK 65m

Dec 31 2021SEK 5mSEK 3m

-SEK 45m

Sep 30 2021n/an/a

-SEK 55m

Jun 30 2021n/an/a

-SEK 74m

Mar 31 2021n/an/a

-SEK 73m

Dec 31 2020SEK 4mSEK 2m

-SEK 72m

Sep 30 2020n/an/a

-SEK 73m

Jun 30 2020n/an/a

-SEK 65m

Mar 31 2020n/an/a

-SEK 44m

Dec 31 2019SEK 3mSEK 2m

-SEK 46m

Sep 30 2019n/an/a

-SEK 43m

Jun 30 2019n/an/a

-SEK 40m

Mar 31 2019n/an/a

-SEK 32m

Dec 31 2018SEK 3mSEK 2m

-SEK 41m

Sep 30 2018n/an/a

-SEK 26m

Jun 30 2018n/an/a

-SEK 22m

Mar 31 2018n/an/a

-SEK 37m

Dec 31 2017SEK 3mSEK 1m

-SEK 36m

Compensation vs Market: Staffan's total compensation ($USD482.38K) is above average for companies of similar size in the Swedish market ($USD234.97K).

Compensation vs Earnings: Staffan's compensation has been consistent with company performance over the past year.

CEO

Staffan Stromberg (57 yo)

11.8yrs

Tenure

SEK 5,327,000

Compensation

Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...

Leadership Team

NamePositionTenureCompensationOwnership
Staffan Stromberg
Chief Executive Officer11.8yrsSEK 5.33m0.79%
SEK 4.1m
Maria Ekdahl
Chief Financial Officer2.2yrsno data0.035%
SEK 179.8k
Anders Kronström
Chief Operating Officer6.8yrsSEK 500.00k0.083%
SEK 427.6k
Thomas Schnitzer
Chief Scientific Officerless than a yearno datano data
Sanjiv Sharma
Head of Medical Affairsless than a yearno datano data
Jonas Rastad
Chief Medical Officerless than a yearno datano data

1.5yrs

Average Tenure

57yo

Average Age

Experienced Management: IBT B's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Peter Rothschild
Chairman13.8yrsSEK 727.00kno data
Margareta Hagman
Independent Director9.2yrsSEK 153.00k0.039%
SEK 201.8k
Eva Idén
Independent Director7.5yrsSEK 153.00k0.0042%
SEK 21.4k
Kristina Nygren
Independent Director6.5yrsSEK 153.00k0.00074%
SEK 3.8k
Anthon Jahreskog
Independent Director7.5yrsSEK 193.00k0.18%
SEK 927.1k

7.5yrs

Average Tenure

58yo

Average Age

Experienced Board: IBT B's board of directors are considered experienced (7.5 years average tenure).